Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner
RefinitivMeno di 1 minuto di lettura
Kazia Therapeutics Ltd 
KZIA:
KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER
KAZIA THERAPEUTICS LTD - SEEKS FDA FEEDBACK ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Accedi o crea un account gratuito per leggere queste notizie